Updates on hormone receptor-positive HER2-negative breast cancer

Bookmark and Share
Published: 26 Jul 2019
Views: 1877
Dr Aurelio Castrellon - Memorial Healthcare System, Hollywood, FL, USA

Dr Aurelio Castrellon speaks to ecancer at the 2019 ASCO Direct Highlights Symposium in Miami about the important developments in the treatment of hormone receptor-positive HER2-negative breast cancer.

He describes two main studies in patients with stage IV breast cancer, specifically in premenopausal patients and includes the MONALEESA-7 trial and the KCSG-BR 15-10 study.

Dr Castrellon also details two further studies which assessed the use of pembrolizumab combined with eribulin in this disease setting and the combination of fulvestrant with capivasertib (an AKT-inhibitor).

He concludes by mentioning the mutation FAT1, which may confer intrinsic resistance to CDK4/6 inhibition in these patients.


  • Categories: